Abstract
In 2019, the coronavirus pandemic broke out as a serious public health issue worldwide. In Côte d’Ivoire, the number of cases of COVID-19 has increased rapidly. The Severe Acute Respiratory Syndrome virus (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2) receptors in the respiratory tracts and enters the respiratory and alveolar cells of infected patients. Deficiency of fat-soluble vitamin D3 is associated with respiratory distress syndrome and pulmonary fibrosis by activation of the renin-angiotensin system. In Côte d’Ivoire, very little research is being done on SARS-CoV-2 and vitamin D. The objective of this study was to assess the vitamin D status of people infected and suffering from COVID-19 in order to contribute to their medical treatment. The study involved 100 adults infected with SARS-CoV-2 (24 women and 76 men). After confirmation of the patient’s SARS-CoV-2 status by RT-PCR, the 25 (OH) vitamin D assay was performed on the Cobas 6000 device and compared to control subjects, the non-COVID-19 positive. A significant decrease in 25-hydroxy vitamin D3 concentrations (44 ± 1.29 nmole/L) was observed in patients infected with SARS-CoV-2, compared to control (78 ± 0.68 nmole/L) (p 3 deficiency requires vitamin D supplementation in the management of hospitalized patients infected with SARS-CoV-2.
Highlights
SARS-CoV-2 infection is a public health problem that has infected 314,207,645 million people since January 12, 2022, and killed 5,521,807 million worldwide [1] [2]
After confirmation of the patient’s SARS-CoV-2 status by RT-PCR, the 25 (OH) vitamin D assay was performed on the Cobas 6000 device and compared to control subjects, the non-COVID-19 positive
The main objective of this study was to determine the 25-hydroxy vitamin D3 status in patients infected with SARS-CoV-2
Summary
SARS-CoV-2 infection is a public health problem that has infected 314,207,645 million people since January 12, 2022, and killed 5,521,807 million worldwide [1] [2]. The high mortality rate primarily concerned people who already had other chronic diseases. In Africa, 3.7 million people are infected with SARS-CoV-2 with a low mortality rate while the impact of the pandemic remains uncertain [3]. During COVID-19 infection, SARS-CoV-2 virus binds to angiotensin converting enzyme 2 (ACE2) receptors in the respiratory tracts of infected patients, to enter respiratory and alveolar cells [4] [5] and uses the TMPRSS2 serine protease for host cell priming. Type II pneumocytes, on which the ACE2 receptors are strongly expressed, represent the main target of SARS-CoV [8] [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
